Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Tongue Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 65Cisplatin 42Cetuximab 36Radiotherapy 28Nivolumab 26Paclitaxel 22Carboplatin 22Docetaxel 20durvalumab 14Radiotherapy, Intensity-Modulated 12Fluorouracil 12Cyclophosphamide 11tremelimumab 9Gemcitabine 9Ipilimumab 8fludarabine 7avelumab 7Erlotinib Hydrochloride 7toripalimab 6epacadostat 6cemiplimab 6Radiosurgery 6Interleukin-2 6Capecitabine 6Bevacizumab 6spartalizumab 5Celecoxib 5zalutumumab 4tislelizumab 4fludarabine phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × advexin × Head & Neck × Clear all
NCT02842125 2020-06-02

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

MultiVir, Inc.

Phase 1/2 Terminated
4 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis

NCT00064103 2013-01-23

Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

National Cancer Institute (NCI)

Phase 1/2 Completed
51 enrolled
Head & Neck

Mouth Neoplasms, Oropharyngeal Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡